PRODUCT TYPES – Page 4

API particle size distribution failure after re-crystallization parameter adjustment: how to justify reprocessing vs rejection to FDA/EMA inspectors

The initial signs of an API particle size distribution failure often manifest both on the production floor and within laboratory environments. Understanding these symptoms is vital for prompt investigation. Common…

API hygroscopicity-driven degradation during routine release testing: data integrity and chromatographic audit trail review steps

Understanding the symptoms associated with API hygroscopicity-driven degradation is the first step in addressing this issue. Common indicators may occur during routine release testing or within stability studies. Here are…

API nitrosamine risk exceedance during routine release testing: data integrity and chromatographic audit trail review steps

Identifying the symptoms or signals of nitrosamine risk exceedance is pivotal in initiating an effective investigation process. Common indicators may include:Click to read the full article.

API photostability failure during CPV trending review: regulatory impact assessment and change control remediation plan

Symptoms of photostability failures can manifest in various ways during routine CPV trending reviews. Some key signals to look for include:Click to read the full article.

API XRPD mismatch during process validation campaign: data integrity and chromatographic audit trail review steps

Identifying symptoms or signals indicative of an XRPD mismatch during a process validation campaign is critical for timely intervention. Common observable symptoms include:Click to read the full article.

API color / appearance change during commercial scale manufacture: control strategy updates for CPPs/CMAs and continued process verification

The first step in addressing API color or appearance changes is recognizing and documenting symptoms as they manifest on the manufacturing floor or laboratory. Key signals may include:Click to read…

API packaging moisture ingress issue after solvent change in last step: GMP investigation checklist and batch disposition evidence pack

Identifying the initial symptoms of moisture ingress is crucial for effective investigations. Healthcare companies often overlook these early signs, leading to larger quality issues. Typical signals include:Click to read the…

API impurity profile OOS after cleaning validation requalification: data integrity and chromatographic audit trail review steps

The onset of OOS results typically manifests through specific signals from manufacturing or laboratory environments. First and foremost, signs of these deviations may include:Click to read the full article.

API photostability failure after equipment maintenance intervention: control strategy updates for CPPs/CMAs and continued process verification

Control Strategy Updates Following API Photostability Failure After Equipment Maintenance Intervention In the pharmaceutical manufacturing landscape, maintaining strict compliance with Good Manufacturing Practices (GMP) is essential for ensuring product quality…

API melting point / DSC anomaly during EU GMP inspection preparation: control strategy updates for CPPs/CMAs and continued process verification

Detecting an abnormal melting point during DSC analysis is the primary indicator of a potential issue with the API. Other symptoms may include:Click to read the full article.

API hygroscopicity-driven degradation after solvent change in last step: data integrity and chromatographic audit trail review steps

Detecting the early symptoms of API degradation is crucial. Observations can include:Click to read the full article.

API stability failure at accelerated conditions during stability pull at 6/12 months: supplier qualification gaps and incoming testing upgrades to close the loop

Identifying symptoms indicative of stability failures is crucial for timely responses. Common signals include:Click to read the full article.